| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL3 |
| Uniprot No | P43628 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-245aa |
| 氨基酸序列 | HEGVHRKPSL LAHPGPLVKS EETVILQCWS DVRFQHFLLH REGKFKDTLH LIGEHHDGVS KANFSIGPMM QDLAGTYRCY GSVTHSPYQL SAPSDPLDIV ITGLYEKPSL SAQPGPTVLA GESVTLSCSS RSSYDMYHLS REGEAHERRF SAGPKVNGTF QADFPLGPAT HGGTYRCFGS FRDSPYEWSN SSDPLLVSVT GNPSNSWPSP TEPSSETGNP RHLH |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL3重组蛋白的3篇参考文献及其摘要概括：
1. **"Structural and Functional Analysis of KIR2DL3 Reveals Insights into HLA-C Recognition"**
*Authors: Smith A, et al.*
**摘要**: 本研究通过重组表达KIR2DL3胞外结构域，解析其晶体结构，揭示了该受体与HLA-C1配体结合的分子机制，并验证了特定氨基酸残基对亲和力的调控作用。
2. **"Recombinant KIR2DL3 Inhibits NK Cell Cytotoxicity in HLA-C-Dependent Manner"**
*Authors: Zhang L, et al.*
**摘要**: 利用重组KIR2DL3蛋白进行体外功能实验，证明其可竞争性抑制自然杀伤细胞(NK)对表达HLA-C1靶细胞的杀伤活性，为免疫调节疗法提供了实验依据。
3. **"Allelic Variations of KIR2DL3 Recombinant Proteins Alter Ligand Binding Specificity"**
*Authors: Johnson R, et al.*
**摘要**: 通过构建不同基因多态性的KIR2DL3重组蛋白变体，发现特定单核苷酸多态性(SNPs)显著改变其与HLA-C的结合能力，提示遗传变异可能影响感染性疾病易感性。
---
**备注**：以上文献信息为示例性虚构内容(基于真实研究方向的合理推测)，实际文献需通过PubMed或Web of Science检索关键词如“KIR2DL3 recombinant protein”获取。若需具体文献，建议补充研究领域细分方向(如结构生物学/肿瘤免疫/病毒感染)。
**Background of KIR2DL3 Recombinant Protein**
KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor 2DL3) is a member of the KIR family, a group of transmembrane proteins primarily expressed on natural killer (NK) cells and subsets of T lymphocytes. These receptors play a critical role in regulating immune responses by interacting with major histocompatibility complex (MHC) class I molecules on target cells. KIR2DL3 is an inhibitory receptor characterized by two extracellular immunoglobulin-like domains (D0 and D2) and a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon binding to specific HLA-C ligands (e.g., HLA-C1 allotypes), KIR2DL3 transmits inhibitory signals that suppress NK cell cytotoxicity and cytokine production, thereby preventing attacks on healthy self-cells and maintaining immune tolerance.
Recombinant KIR2DL3 protein is engineered using biotechnological methods, often expressed in mammalian or insect cell systems to ensure proper post-translational modifications. This protein retains the functional extracellular domain required for ligand interaction, enabling its use in structural studies, binding assays, and functional analyses. Research on KIR2DL3 has implications for understanding immune evasion mechanisms in viral infections, cancer progression, and pregnancy-related immune tolerance. Additionally, it serves as a tool for developing therapies targeting NK cell activity, such as in autoimmune diseases or to enhance antitumor responses.
Polymorphisms in KIR2DL3 and its ligands are linked to disease susceptibility, including viral outcomes (e.g., hepatitis C, HIV) and reproductive disorders. Studying recombinant KIR2DL3 helps unravel these associations and informs precision medicine strategies. Its role in transplantation immunity also makes it relevant for improving graft survival by modulating NK cell-mediated rejection. Overall, KIR2DL3 recombinant protein is a vital resource for advancing immunology research and therapeutic innovation.
×
